首页> 外文期刊>Sleep & breathing =: Schlaf & Atmung >Titratable mandibular repositioner appliances for obstructive sleep apnea syndrome: are they an option?
【24h】

Titratable mandibular repositioner appliances for obstructive sleep apnea syndrome: are they an option?

机译:可滴定的下颌定位器矫治器用于阻塞性睡眠呼吸暂停综合症:是否可以选择?

获取原文
获取原文并翻译 | 示例
       

摘要

Mandibular repositioning appliances (tMRAs) designed with a titratable mechanism are effective to treat obstructive sleep apnea syndrome (OSAS) but are not widely used, although many studies have proven their value. The aim of the present study was to evaluate the efficacy of tMRAs in the treatment of OSAS on the criteria of the American Academy of Sleep Medicine (AASM; apnea/hypopnea index [AHI] < 5). Three hundred consecutive patients with a polysomnographic diagnosis of OSAS were referred for treatment with tMRAs between 2000 and 2003. Thirty-eight patients were excluded, and 262 concluded the titration protocol with tMRA that lasted 4 months. After titration, the patients were referred for a medical reassessment, and 83 patients (70 men) participated in the new polysomnographic exam with tMRA in place to access tMRA's efficacy. The mean pre- and post-treatment AHI were 26 +/- 17.7 and 4.8 +/- 5.3 events per hour, respectively (p < 0.00005). Fifty-three (62.6%) of the 83 patients were treated successfully (AHI < 5). Twenty-three patients had severe OSAS, and 12 of them (52.1%) were treated successfully (AHI < 5). Forty patients had moderate OSAS, and 26 of them (65%) were treated successfully. Twenty patients had mild OSAS, and 15 (75%) were successfully treated. Even when applying more rigid criteria such as those of the AASM, the expressive success rate obtained with the treatment of different degrees of OSAS indicates that tMRAs are an additional valuable option even for cases of severe apnea in which the patient does not tolerate continuous positive airway pressure or cannot afford this treatment, a fact quite common in Brazil and other developing countries.
机译:设计有可滴定机制的下颌复位器具(tMRA)可有效治疗阻塞性睡眠呼吸暂停综合症(OSAS),但并未得到广泛使用,尽管许多研究已证明它们的价值。本研究的目的是根据美国睡眠医学学会(AASM;呼吸暂停/呼吸不足指数[AHI] <5)的标准评估tMRA在OSAS治疗中的疗效。在2000年至2003年之间,连续300例经多导睡眠图诊断为OSAS的患者被转诊接受tMRA治疗。38例患者被排除在外,其中262例总结了持续4个月的tMRA滴定方案。滴定后,将患者转诊进行医学评估,有83例患者(70名男性)参加了新的多导睡眠图检查,并接受了tMRA的检测,以了解tMRA的疗效。治疗前后的平均AHI分别为每小时26 +/- 17.7和4.8 +/- 5.3个事件(p <0.00005)。 83例患者中有53例(62.6%)得到了成功治疗(AHI <5)。 23例严重OSAS患者,其中12例(52.1%)成功治疗(AHI <5)。 40例中度OSAS患者,其中26例(65%)被成功治疗。 20例患者患有轻度OSAS,其中15例(75%)被成功治疗。即使采用更严格的标准(例如AASM的标准),通过不同程度的OSAS治疗获得的成功率也表明,tMRA是另一种有价值的选择,即使对于严重的呼吸暂停患者不能耐受持续的阳性气道压力或负担不起这种治疗,这在巴西和其他发展中国家很普遍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号